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The malignant transformation of normal cells into cancer cells result in the loss of control of 
cellular regulatory mechanisms such as loss of function of tumour suppressors and gain of function 
of oncogenes. Genetic mutations may be inherited or acquired during the process of malignant 
transformation, such that the normal mechanisms responsible for control cellular proliferation 
become dysfunctional. 
 Aberrations of the BCLAF1 gene located on chromosome 6q23 has previously been detected by 
whole genome sequence analysis of DNA from oesophageal cancer biopsies. Although the role of 
BCLAF1 is not well defined, some studies have shown BCLAF1 to have functional connections 
linked to some of the known hallmarks of cancer such as cell proliferation, apoptosis and genome 
stability, thus linking BCLAF1 to cellular transformation.  
The objective of the study was to examine the effects of BCLAF1 knockdown/BCLAF1 knockout 
studies in cellular gene expression and tumorigenesis. BCLAF1 expression was significantly 
reduced in the immortalized keratinocyte cell line (HaCaT), a lung transformed fibroblasts cell 
line (CT1), cervical cancer cell line (HeLa), breast cancer cell line (MDA-231) and two 
oesophageal cancer cell lines (KYSE30 and WHCO1), with a highly significant reduction in the 
breast cancer cell line (MDA-231). siRNA mediated knockdown of BCLAF1 resulted in altered 
expression of several downstream genes including downregulation the proapoptotic genes 
Caspase-3 and BAX and the DNA damage repair genes EXO1, ATRIP and BACH1. BCLAF1 
deficiency also attenuated P53 expression and slightly increased P21 expression resulting in a 
P21-dependent G1 phase cell cycle arrest.  To our knowledge, this is the first study to identify 
H2AX as a downstream gene of BCLAF1 that is downregulated by BCLAF1 knockdown. 
Abrogation of BCLAF1 in CT1 cells resulted in P53-dependent uncontrolled growth of cells, 








Cancer is a malignant transformation of normal cells to cancer cells, an abnormal growth of cells 
that if not controlled and stopped could metastasize (Hahn et al., 1999). Such malignant 
transformation results in loss of control of cellular regulatory mechanisms due to loss of function 
of tumour suppressors and gain of function of oncogenes (Jurel et al., 2014). During malignant 
transformation, cancer cells accumulate genetic mutations that overpower the normal mechanisms 
that control cellular proliferation (Griffiths et al., 2000). All cancer cells share common hallmarks 
that make them differ from neighbouring normal cells, these are 1. Stimulation  and sustaining 
proliferative signalling, 2. Evasion of growth suppressors, 3. Evasion of apoptosis, 4. Enable 
replicative immortality; 5. Induce angiogenesis, 6. Activate invasion and metastasis, 7. 
Reprogramming of energy metabolism and 8. Evasion of the immune system (Hanahan & 
Weinberg, 2000; Hanahan & Weinberg, 2011). 
The concept of ‘Hallmarks of cancer’ particularly guides translational research aimed at the 
improvement and development of biomarkers screening tests for early and rapid detection, 
precision medicine and quality of life for cancer patients (Hainaut & Plymoth, 2013). Single gene 
or multi-gene signatures are used as predictive biomarkers to measure specific molecular pathway 
deregulations in cancer (Goossens et al., 2015). The gain of function in oncogenes disrupt the 
normal regulation of the cell signalling leading to deregulation of many cell pathways including 
cell cycle, apoptosis and invasion which eventually lead to cancer development (Giancotti, 2014). 
Cancer is associated with mutations in oncogenes and tumour suppressor genes which cause cells 
to undergo transformation leading to genomic instability (Albertson et al., 2003). The changes in 
DNA sequence can be INDELS (insertions and deletions), duplications, genomic rearrangements, 
loss of heterozygosity in somatic cells or inherited mutated genes (Popova et al., 2009). Detection 
of structural variations and patterns in genes contribute to cancer genome analysis and 




Tumour suppressor genes act in normal cells to suppress proliferation, by negatively regulating 
cell proliferation, and act through inhibition of the expression of a proto-oncogene or the activity 
of its protein (Marshall, 1991). Loss of function in tumour suppressors or the lack of these tumour 
suppressor genes in cancer cells exhibit uncontrolled cell growth associated with malignancy 
(Heaney & Melmed, 2005). In addition, abnormalities in tumour suppressor genes are the most 
frequently found in human tumours (Vogelstein & Kinzler, 1992; Soussi et al., 2000). The 
identification of these abnormalities in tumour suppressors DNA has greatly facilitated the studies 
and understanding of human tumours and identification of specific genetic markers that are 
repeatedly reduced to homozygosity in several tumours of a type (Hahn & Weinberg, 2002).  
BCLAF1 aberrations were detected through whole genome sequencing of DNA from biopsies of 
oesophageal cancer patients (Mwapagha, 2014). The deletion of BCLAF1 had previously been 
shown to be associated with various cancers such as Non-Hodgkin's lymphoma, Burkitt’s 
lymphoma and colorectal cancer (Kasof et al., 1999; Lawrence et al., 2014). BCLAF1 was 
originally identified in a yeast two-hybrid screen of proteins that interact with E1B 19K, and 
subsequently shown as a protein-protein interacting partner with BCL2 family members, 
moreover,  its overexpression induced apoptosis in HeLa cells and suppresses transformation by 
adenovirus E1A and E1B-19K proteins or mutant p53 (Kasof et al., 1999). Subsequent studies 
have suggested roles for BCLAF1 in RNA metabolism processing (Bracken et al., 2008; Sarras et 
al., 2010), lung development and immune system functioning (McPherson et al., 2009). Recent 
studies have shown that, depending on the extent of DNA damage, BCLAF1 is involved in the 
γH2AX-mediated regulation of apoptosis and DNA repair, and is a γH2AX-interacting tumour 
suppressor (Lee, Yu, et al., 2012). Moreover, BCLAF1 is a key component of DNA damage 
induce-BRCA1 protein complex  involved in mRNA splicing, DNA repair, cell-cycle arrest, and 
transcriptional regulation (Savage et al., 2014). Taken together, these studies indicate that BCLAF1 
has functional connections and mutation patterns consistent with the known hallmarks of cancer 
that suggested BCLAF1 contribution to cellular transformation (McPherson, 2012). 
1.2 Structure of BCLAF1 
BCL2-associated transcription factor 1 (BCLAF1), also known as BTF, or bK211L9 is a Bcl-2 
family gene. The BCLAF1 gene encodes 13 exons and is located on chromosome 6q23 where it 
spans 33 782 bases (McPherson, 2012). This region is reported to have a high occurrence of 
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deletions in different tumours, such as Non-Hodgkin's lymphomas, leukaemias and Burkitt’s 
lymphoma (Merup et al., 1998). The nuclear protein encoded by BCLAF1 gene has four isoforms 
generated by alternative splicing with two predominant BCLAF1 forms reported to be of 918 
amino acids and of about 797-846 amino acids, missing 49 amino acids in length. The longer 
isoform with a molecular mass of 106 kDa and a smaller isoform with a molecular mass of 101 
kDa (McPherson, 2012). BCLAF1 localizes throughout the nucleus and slightly in the cytoplasm 
in a punctate-like manner and redistributes to the nuclear envelope loci in cells undergoing 
apoptosis. Its mRNA levels is ubiquitously expressed in skeletal muscle, haematopoietic cells, and 
various other cell lineages (Kasof et al., 1999; McPherson et al., 2009). Steady-state levels of 
BCLAF1 protein fluctuate in a temporal and cell-lineage dependent on the cell model during 
development (McPherson et al., 2009). 
BCLAF1 has been reported to be involved in various biological processes. BCLAF1 was initially 
identified as interacting with the adenoviral homolog E1B19K. Overexpression of BCLAF1 results 
in increased apoptosis and its transcriptional repression and apoptotic role in cells is reversible in 
the presence of BCL2 or BCL-XL (Kasof et al., 1999). However, BCLAF1 does not exhibit any 
structural similarities with the BCL2 family proteins. BCLAF1 has an N-terminal tract of 
Arginine–Serine long repeats (RS domain) (Figure 1.1) that is typically involved in pre-mRNA 
processing and is present in interchromatin granule clusters, nuclear substructures that act as 
repositories for mRNA splicing and transcription factors (Valcárcel & Green, 1996; Saitoh et al., 
2004). Although BCLAF1 and antiapoptotic BCL2 members have been shown to have no common 
structural similarities, BCL2 protein interacts with BCLAF1 and prevent its localization to the 
nuclear envelope (Kasof et al., 1999). Several studies have elaborated more on the link between 
BCLAF1, apoptosis and transcription (Sarras et al., 2010). Protein kinase C δ (PKCδ) upregulates   
P53 gene transcription through the core promoter element (CPE-TP53) in the P53 promoter, 
BCLAF1 is a trigger for protein kinase C δ-dependent P53 gene transcription by interacting with 
CPE-TP53. Moreover, disruption of BCLAF1-mediated P53 gene transcription leads to 
suppression of P53-mediated apoptosis in response to DNA damage (Liu et al., 2007). Indeed, 
several functional links have been described for BCLAF1 by different research groups in different 
biological processes, such as mRNA splicing and DNA repair (Lee, Yu, et al., 2012; Savage et al., 
2014), senescence (Shao et al., 2016), production of Kaposi's sarcoma-associated herpesvirus 
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(Ziegelbauer et al., 2009) and human cytomegalovirus infection  (Lee, Kalejta, et al., 2012), lung 
development and T-cell activation (McPherson et al., 2009). 
1.3 BCLAF1 gene expression patterns in cancer 
BCLAF1 protein is punctate-concentrated throughout the nucleus and its mRNA is prevalently 
expressed in skeletal muscle, hematopoietic cells, and many other cell lineages (Kasof et al., 1999; 
McPherson et al., 2009). BCLAF1 steady-state protein levels fluctuate from cell to cell in a mode-
dependent manner during development. The BCLAF1 locus at 6q23  has a high occurrence of 
deletions in various tumours, such as lymphomas and leukaemias (McPherson et al., 2009), as well 
as in Raji cells, derived from Burkitt's lymphoma, which has deletions in 6q. In addition, BCLAF1 
aberrations were detected in oesophageal cancer biopsies through whole genome sequencing 
(Mwapagha, 2014). Two transcripts corresponding to BCLAF1; the shorter form, btfS and btfL, 
the longer isoform, both appear to be widely expressed but were deleted in some tumours (Kasof 
et al., 1999). Moreover, the full-length isoform, btfL isoform, is significantly over-expressed in 
colon cancer cell lines and colorectal cancer tissue and is associated with elevated colony-
forming ability, suggesting pro-tumorigenic ability for the L isoform in colon cancer cells (Zhou 
et al., 2014). Post neoadjuvant therapy, both nuclear and cytoplasmic overexpression of 
BCLAF1 occurs in rectal cancer and negative and weak nuclear BCLAF1 expressions are 
independently linked with a poor prognosis of rectal cancer (Brown et al., 2016).  
 
Figure 1.1. Protein domains in BCLAF1L and BCLAF1S isoforms. BCLAF1 gene encodes for four splice variants, 
with two predominant BCLAF1 forms; BCLAF1L and BCLAF1S isoforms. The two predominant BCLAF1 forms, 
the longer isoform 920 amino acids in length with a predicted molecular mass of 106 kDa, and smaller isoform of 871 
amino acids long with a predicted molecular mass of 101 kDa respectively. BCLAF1 has an N-terminal tract of 
Arginine–Serine long repeats (RS domain), a C-terminal region of thyroid hormone receptor associated protein 3 




1.4 Mechanisms of BCLAF1 in Tumour Suppression 
BCLAF1 operates via several mechanisms in its anticancer function involving apoptosis, cell 
cycle, DNA damage repair and genomic stability. In its anti-cancer role, BCLAF1 is both 
directly and indirectly involved in the activation and stabilization of complexes involved in 
different signalling pathways. BCLAF1 co-localizes with γH2AX and stabilizes the 
Ku70/DNAPKcs complex which facilitates non-homologous end joining double strand breaks 
repair and induces the disassociation of anti-apoptotic Ku70/BAX complex in the cytoplasm, 
which liberates and activate proapoptotic BAX, promoting pro-apoptotic activity of Caspase-3 
or Caspase-9 (Y. Y. Lee et al., 2012). BCLAF1 is a key component of BRCA1-mRNA splicing 
complex involved in mRNA splicing and stabilization of genes such as ATRIP, EXO1 and 
BACH1 required for efficient DNA repair and maintenance of genomic stability (Savage et al., 
2014). BCLAF1 initiates apoptosis in severely compromised cells through the induction of 
mitochondrial-mediated apoptotic pathway and by disturbing P21-mediated inhibition of 
Caspase/cyclin E-dependent apoptotic pathway (Kasof et al., 1999; Lee, Yu, et al., 2012). 
BCLAF1 is essential for the DNA damage-induced senescence and it’s an important NF-κB 
signal transducer (Shao et al., 2016). 
1.5 BCLAF1 and the Hallmarks of cancer 
1.5.1 BCLAF1 in Apoptosis pathway 
Apoptosis is a genetically controlled process of cell death which plays a key role in maintaining 
homeostasis and preventing the development of multiple diseases. Disruption and evasion of 
apoptosis leads to cancer (Kasof et al., 1999; Hanahan & Weinberg, 2000; Hanahan & Weinberg, 
2011). The BCL2 family consists of highly conserved proteins with different biological functions, 
many of the BCL2 members are the major regulators of apoptosis through multiple mechanisms 
(White, 1996). Overexpression of BCLAF1 induced apoptosis in Hela cells (Kasof et al., 1999). 
Recent studies indicate that BCLAF1 induces apoptosis in various cell types (Shao et al., 2016). 
Overexpression of BCLAF1 induces a pro-apoptotic BAX activity. siRNA-mediated BCLAF1 
knockdown leads to reduced BAX expression, along with reduced activity of the BAX-downstream 
pro-apoptotic Caspase-9 and Caspase-3 (Sarras et al., 2010). In addition, BCLAF1 plays a role in 
disrupting the P21-dependent inhibition of activation of Caspase-dependent mitochondrial-
mediated apoptotic pathways by negatively regulating P21 expression in irradiated cells (Sarras et 
al., 2010; Lee, Yu, et al., 2012). In response to DNA damage-induced apoptosis, BCLAF1 induces 
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the P53-mediated apoptosis by activating P53 gene transcription through PKCδ-BCLAF1 
signalling (Liu et al., 2007). Moreover, downregulation of BCLAF1 is associated with Ku70-bound 
BAX complex formation in the cytoplasm, suggesting that BCLAF1 is essential for the release of 
BAX from the anti-apoptotic Ku70–BAX complex (Lee, Yu, et al., 2012) (Figure 1.2A-B).  
 
 
Figure 1.2A &1.2B. Mechanistic representation of various BCLAF1 roles in various signalling pathways. In the 
presence of BCLAF1, following a site-specific phosphorylation of BCLAF1 by DNA-PKs induces the localization of 
BCLAF1 to the nuclear envelope, there it merges with γH2AX foci, which in turn stabilizes the Ku70/DNA-PKcs 
complex involved non-homologous end joining double strand break repair. Meanwhile in the cytoplasm, BCLAF1 
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induces the dis-association of Ku70/BAX complex, liberating active proapoptotic BAX. BCLAF1 regulates both 
cyclin E and P53/P21dependent mitochondria-mediated pathways and inducing pro-apoptotic activity of Caspase-3. 
In contrast, in BCLAF1 depleted cells, the Ku70/DNA-PKcs complex formation is weakened and depleted, 
subsequently reducing the activity of DNA repair contributing to cell survival with defective NHEJ DNA repair. 
Furthermore, there’s inhibition of the phosphorylation of BCLAF1 by DNA-PKcs, hence, no translocation of BCLAF1 
to the nucleus.  In the cytoplasm, suppressed BCLAF1 results in more Ku70bound BAX, which inhibits the formation 
of pro-apoptotic BAX and pro-apoptotic Ku70-p18-Cyclin E complex. Modified from (Lee, Yu, et al., 2012). 
 
1.5.2 BCLAF1 in DNA repair 
Cells activate specific pathways for cell fate decisions depending on the severity of DNA damage. 
BCLAF1 is involved in the γH2AX-mediated double strand DNA damage recognition and repair 
pathway (Lee, Yu, et al., 2012). Through a site-specific phosphorylation of BCLAF1 by DNA-
PKcs, BCLAF1 translocates to the nuclear envelope where it binds to γH2AX and regulates 
Ku70/DNA-PKcs complex stabilization which facilitate the non-homologous end joining (NHEJ) 
DNA double strand repair (Figure 1.2). Furthermore, BCLAF1 positively regulate P53 expression 
by interacting CPE-TP53 during DNA damage (Liu et al., 2007). γH2AX accumulates DNA 
lesions in the nucleus, serving as the scaffold to temporarily assist BCLAF1, to access CPE-TP53, 
leading to upregulation of P53 mRNA and protein levels in the irradiated cells (Lee, Yu, et al., 
2012). Subsequent studies indicated further roles for BCLAF1 in DNA repair (Savage et al., 2014; 
Orr & Savage, 2015). BCLAF1 mediates the formation of a BRCA1-mRNA splicing-DNA 
damage-induced protein complex with other spliceosome proteins such as Prp8, U2AF35/65, 
SF3B1 through BRCA1 mediated pathway which is involved in the regulation of mRNA splicing 
of several genes in response to DNA damage. BRCA1/BCLAF1-mediated mRNA splicing in 
response to DNA damage serves as a mechanism for the processing of key pre-mRNAs required 
for an effective DNA damage response and DNA repair. BRCA1 and BCLAF1 function in an 
epistatic manner within the same pathway. In addition, BRCA1/BCLAF1 mRNA splicing complex 
acts as a tumour suppressor complex, functioning to boost and promote the splicing and stability 
of genes required for DNA repair and maintenance of genomic stability.  Depletion or loss of 
BRCA1/BCLAF1-mediated splicing of ATRIP, BACH1, and EXO1 results in reduced but not 
abolished protein levels after DNA damage and in sensitivity to DNA damage and defective DNA 
repair (Savage et al., 2014).  
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1.5.3 BCLAF1 and the cell cycle 
BCLAF1 is involved in P21-dependent cell cycle regulation. siRNA-mediated BCLAF1 
knockdown studies in human fibroblast cells attenuated P53 expression but led to significant 
increases in P21 expression, suggesting that BCLAF1 is involved in P21 regulation and induction 
P21-dependent G1 cell cycle arrest (Lee, Yu, et al., 2012). Previous studies suggested that 
BCLAF1 is a part of a complex that regulates cyclin D1 mRNA stability (Bracken et al., 2008). 
Cyclin D1 and cyclin E are the essential components for regulating the cell cycle at either early G1 
or late G1/S transition (Murray, 2004). BCLAF1 knockdown suppressed the expression of cyclin 
D1 (Lee, Yu, et al., 2012), indicating that BCLAF1 affects cell cycle progression by regulating the 
P21-dependent cyclins in early G1, which is often dysregulated in human cancers (Abbas & Dutta, 
2009). 
1.5.4 BCLAF1 in mRNA splicing 
BCLAF1 contains a Serine-Arginine rich region within its N terminus, present in many pre-mRNA 
processing factors and is involved in pre-mRNA processing and splicing (Ca´ ceres, 1997). 
BCLAF1 forms part of a mRNA splicing complex together with SNIP1, SkIP, TAP150, and Pinin 
proteins which is required for the production of stable spliced Cyclin D1 transcripts (Bracken et 
al., 2008). BCLAF1 is important in pre-mRNA splicing and interaction with various core splicing 
machinery proteins (Merz et al., 2007). Savage and colleagues demonstrated that BCLAF1 
interacts with a number of other core mRNA splicing proteins such as Prp8, U2AF65, U2AF35, 
and SF3B1, within the BRCA1/BCLAF1 mRNA splicing complex. Independently of DNA 
damage, this interaction promotes efficient splicing and stability of several genes, such as; ATRIP, 
BACH1, and EXO1 transcripts (Savage et al., 2014; Orr & Savage, 2015). 
1.5.5 BCLAF1 role in T-cell activation and immune system functioning 
Given the role of BCLAF1 in apoptosis, McPherson and others demonstrated the critical functional 
role of BCLAF1 in lymphocyte homeostasis, activation and the immune system. Although 
BCLAF1 is non-essential for T cells development, it is required for maintenance of B- and T-cell 
homeostasis (McPherson et al., 2009). In addition, depletion of BCLAF1 results in the dysregulated 
activation of T cell proliferation but not B cells, and a significant decrease in T cells in the S-phase 
and an increase at the G1 and G2/M phases of the cell cycle as compared to the BCLAF1 wild type. 
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Thus confirming that BCLAF1 is required for proper proliferation and activation of T lymphocytes 
(McPherson et al., 2009; Kong et al., 2012). 
1.5.6 Other BCLAF1 roles 
Besides the functional roles of BCLAF1 in cancer, various researchers investigated the roles of 
BCLAF1 in other processes such as skeletal muscle differentiation, smooth muscle and lung 
development (McPherson et al., 2009; Sarras et al., 2010; Sarras, 2012). In vivo studies on the 
analysis of BCLAF1 deficiency on muscle differentiation indicated that BCLAF1 deficiency 
reduced the number of myoblastic cells in muscle compared to BCLAF1 wild type controls (Sarras, 
2012), although the whole concept is not well understood. Furthermore, BCLAF1 expression is 
significantly upregulated during the saccular stage of mice embryonic lung development and 
surprisingly, BCLAF1 deficient mice primarily die as neonates with defects in end-stage lung 
development that compromise survival (McPherson et al., 2009).  
1.6 BCLAF1 deregulation is a hallmark of tumorigenesis 
BCLAF1 is intrinsically suppressed in tumour cells with natural radio-resistance (Lee, Yu, et al., 
2012). Mutational inactivation of BCLAF1 occurs in different tumours and various biological 
processes concomitant with tumorigenesis. Deregulation or inactivation of BCLAF1-proapoptotic 
and DNA repair factors contribute to apoptotic resistance and cell survival with defective DNA 
repair which is associated with tummourigenesis (Lee, Kalejta, et al., 2012). Various BCLAF1 
knockdown mechanisms indicate that the downstream effects of BCLAF1 deficiency is similar to 
mutant BCLAF1 effects, including reduced apoptotic cells (Kasof et al., 1999; Sarras et al., 2010; 
Lee, Kalejta, et al., 2012), reduced frequency of BCLAF1 translocation to the nuclear envelope 
affecting the γH2AX-BCLAF1 complex activity (Lee, Kalejta, et al., 2012), moreover, tumour 
suppressor BRCA1/BCLAF1 mRNA splicing complex  activity is supressed (Savage et al., 2014), 
P21-dependent cell arrest at G1 phase or re-entry to S phase with replicating the errors caused by 
DSBs (Lee, Kalejta, et al., 2012) and all events that are crucial in tumourigenesis . 
1.7 Clinical and therapeutic implications of BCLAF1 dysfunction 
BCLAF1 plays a critical role in apoptotic signalling (Kasof et al., 1999). Apoptosis  crucial in the 
efficient removal of damaged cells such as those occurring  after DNA damage or during 
development and cell homeostasis (Fuchs & Steller, 2011). Apoptosis can be used as a vehicle  for 
targeted treatment in cancer and deregulation of BCLAF1 expression and cell death signalling is 
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associated with uncontrolled cell proliferation, development and progression of cancer (Pistritto et 
al., 2016). Understanding the apoptotic  mechanisms  and therapeutic strategies co-targeting 
molecules involved in apoptotic resistance can be used to restore cancer cell sensitivity to 
apoptosis and overcome the ineffectiveness of  certain drugs (Giménez-Bonafé et al., 2009). The 
critical role of BCLAF1 contributes to effective maintenance of DNA integrity and genomic 
stability (Lee, Kalejta, et al., 2012; Savage et al., 2014). The BCLAF1 interacting partner THRAP3 
functions together in the BRCA1/BCLAF1 complex to promote the splicing of precursor mRNA 
and export of target transcripts  (Savage et al., 2014). Mutant BCLAF1/THRAP3 in tumours could 
be targets for DNA damaging chemotherapy (Vohhodina et al., 2017).   
1.8 The use of RNAi technology and CRISPR/Cas9 system for gene function validation 
RNA interference (RNAi) and clustered regularly-interspaced short palindromic repeats 
(CRISPR)-associated 9 (CRISPR/Cas9) are powerful genetic tools for validating gene function in 
biological science research and provides a promising therapeutic modality for cancer and other 
genetic diseases (Guo et al., 2013; Haussecker, 2016). Both RNA interference and CRISPR/Cas9 
technologies are RNA-guided mechanisms that cause the cleavage at targeted loci in the genomic 
DNA sequence complementary to their specific sequences and they can be applied in specific 
biological processes in vivo and in vitro (Guo et al., 2013; Haussecker, 2016). With the advent of 
large-scale gene knockdown and knockin/knockout using siRNA libraries and CRISPR/Cas9 
respectively, it has become possible to quickly identify novel drug targets as well as explore their 
roles in tumorigenesis (Morgan-Lappe et al., 2006; Nickles et al., 2012; Boyer et al., 2013; Radia 
et al., 2013; Sánchez-Rivera & Jacks, 2015; Khan et al., 2016).  
Even though functional connections and mutation patterns of BCLAF1 consistent with the known 
hallmarks of cancer are known, the molecular role and contribution of BCLAF1 in tumourigenesis 
remain unclear. siRNA-mediated BCLAF1 knockdown and CRISPR/Cas9-mediated BCLAF1 
knockout studies were done in transformed human lung fibroblast CT1 cell line to examine the 
role of BCLAF1 knockdown and deletion in tumourigenesis. 
1.9 Objective of the study 
Whole genome sequencing studies of oesophageal cancer biopsies have shown BCLAF1 
aberrations in oesophageal cancer (Mwapagha, 2014). Furthermore, BCLAF1 deletions have been 
observed in a number tumour types, and very little is known about BCLAF1 expression patterns in 
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human cancers and its deficiency/presence effects on gene expression, and tumourigenisis (Kasof 
et al., 1999; Zhou et al., 2014). The main objective of the study was to look at the effects of 
BCLAF1 knockdown/knockout studies in fibroblast cells on cellular gene expression and 
tumorigenesis. 
1.10 Aims of the study 
1. Expression patterns of BCLAF1 in different cancer cell lines.  
2. Effects of targeted siRNA-mediated BCLAF1 knockdown and CRISPR/Cas9-mediated 
BCLAF1 knockout studies on cellular gene expression. 
3. Effects of targeted siRNA-mediated BCLAF1 knockdown and CRISPR/Cas9-mediated 


















Expression of BCLAF1 in human tumour cell lines 
2.1 Introduction 
The insight into cancer molecular biology has been revolutionized by next generation sequencing 
technologies.  Next generation sequencing provides cancer gene discovery and identification of 
specific mutations relevant to cancers and other genetic diseases reviewed in (Yadav et al., 2015). 
BCLAF1 is located on chromosome 6q23, a region reported to have a high occurrence of deletions 
in various cancer types including lymphomas and leukaemias (McPherson et al., 2009). In 
addition, cancer associated aberrations have been found in several genes located in this region 
including BCLAF1, suggesting a role in carcinogenesis (Kasof et al., 1999; Mwapagha, 2014). 
Two transcripts of BCLAF1, the shorter and the longer isoform, btfS and btfL respectively are 
widely expressed but deleted in several tumours (Kasof et al., 1999), moreover, the full-length 
isoform (btfL), is significantly over-expressed in colon cancer cell lines and colorectal cancers and 
is associated with elevated colony-forming ability, suggesting pro-tumorigenic ability for the L 
isoform in colon cancer (Zhou et al., 2014). 
Several studies suggested a role for BCLAF1 in different signalling pathways, and a number of 
BCLAF1-associated genes have been identified to date. Over expression of BCLAF1 in HeLa cells 
induces  apoptosis (Kasof et al., 1999). Subsequent studies investigated the role of BCLAF1 role 
in DNA repair (Lee, Yu, et al., 2012; Savage et al., 2014; Shao et al., 2016; Vohhodina et al., 
2017).  Lee and colleagues identified BCLAF1 as a H2AX associated protein involved in the 
regulation of γH2AX-mediated regulation of DNA repair Ku70/DNA-PKcs complex stabilization 
and efficient DNA repair (Lee, Yu, et al., 2012). Furthermore, BCLAF1 is a crucial component of 
the BRCA1/BCLAF1 mRNA splicing complex that is implicated  in the stabilization and efficient 
production of transcripts of various genes  such as EXO1, ATRIP, and BACH1 that are involved in 
DNA repair independently of DNA damage (Savage et al., 2014). BCLAF1 is involved in the 
regulation of the cell cycle by upregulating P21 expression in BCLAF1-deficient cells, resulting 
in a G1 phase cell cycle arrest (Lee, Yu, et al., 2012). 
This chapter examined BCLAF1 expression patterns in a variety of human cancer cell lines and 
the expression of genes linked to BCLAF1 in different cancer signalling pathways such as 




2.2.1 BCLAF1 mRNA and protein expression in cultured transformed and cancer cell 
lines 
BCLAF1 expression was examined in gamma radiation transformed human lung fibroblasts (CT-
1), SV40 immortalized keratinocytes (HaCaT); a cervical cancer cell line (HeLa), a breast cancer 
cell line, (MDA-231) and two oesophageal cancer cell lines (KYSE30 and WHCO1). BCLAF1 
expression in these cell lines was determined by measuring mRNA by real-time polymerase chain 




Figure 2.1. BCLAF1 mRNA and protein expression in different human cell lines. A); RT-PCR analysis of 
BCLAF1 gene expression using RNA extracts from the indicated cell lines and BCLAF1 specific primers (Table 5.5) 
to detect BCLAF1 mRNA expression. B); Western blot analysis of BCLAF1(106kDa) and GAPDH (37kDa) (used as 
a loading control) in protein extracts prepared from the indicated cell lines as described in Materials and Methods.  
 
Analysis of BCLAF1 mRNA by RT-PCR analysis showed BCLAF1 mRNA expression to be 
significantly lower in all the cancer cell lines and an exceptionally low level of expression was 
observed in MDA-231 cell line (Figure 2.1A). The same low levels of BCLAF1 protein were 
observed in the MDA-231 and WHCO1 cell lines (Figure 2.1B). BCLAF1 protein’s half-life is 
shorter in the WHCO1 cells than the KYSE30 cells, which could explain the unrelated results. 
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2.2.2 Genes associated with BCLAF1 
We further investigated the mRNA profiles of genes linked to BCLAF1 in different signalling 
pathways such as apoptosis, DNA repair and cell cycle regulation in the same cell lines.  Firstly, 
genes involved in the apoptosis signalling pathway, the proapoptotic genes such as BAX, Caspase-
3, and Caspase-9 as well as anti-apoptotic BCL2 family members; BCL2, and BCL-XL mRNA 
expressions were examined, following DNA damage repair signalling pathway genes; EXO1, 
BACH1, ATRIP, Ku70, H2AX and BRCA1. We assessed mRNA profiles of cell cycle regulators; 
P53 and P21 in the mentioned cell lines.   
 
Figure 2.2. Proapoptotic and anti-apoptotic gene expression in cultured cell lines. RNA was extracted from the 
transformed cell lines; HaCaT and CT1, cancer cells lines; HeLa, MDA231, KYSE30 and WHCO1 as described in 
Material and Methods and used in RT-PCR analysis for proapoptotic and anti-apoptotic mRNA levels in the indicated 
cell lines.  The specific primer pairs used for each of the selected genes are indicated in Table 5.5. A); Analysis of the 
proapoptotic BAX, Caspase-3 and Caspase-9 genes. B); Analysis of anti-apoptotic BCL2 and BCL-XL genes. 
 
Analysis of proapoptotic (Figure 2.2A) and antiapoptotic (Figure 2.2B) mRNA expression by 
RT-PCR analysis showed proapoptotic BAX and Caspase-3 genes to be reduced in all the cancer 
cell lines, but not the transformed cell lines, while extremely low levels of all three proapoptotic 
gene transcripts were observed in the MDA-231 cell line. Anti-apoptotic BCL2 mRNA levels is 
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low in all cancer and transformed cell lines, in contrast, not much difference was observed in BCL-
XL mRNA expression in MDA-231 and KYSE30 cell lines. 
 
Figure 2.3. DDR genes mRNA expression in cultured cell lines. RNA was extracted from the cells lines as described 
in Material and Methods and used in RT-PCR analysis for genes involved in DDR mRNA levels in the indicated cell 
lines.  The specific primer pairs used for each of the selected genes are shown in Table 5.5. 
 
Mismatch repair and recombination gene EXO1, DNA double-strand break repair genes i.e. 
ATRIP, Ku70 and BRCA1 showed significantly low mRNA expression in all cancer cell lines, 
furthermore, extremely low levels of Ku70, BRCA1 gene transcripts were observed in the MDA-








Figure 2.4. Cell cycle regulators mRNA expression in cultured cell lines. RNA was extracted from the cells lines 
as described in Material and Methods and used in RT-PCR analysis for P53 and P21 mRNA levels in the indicated 
cell lines. P53 and P21 mRNA was quantitated using specific primers as indicated in Material and Methods was 
quantitated using primer pairs as indicated in Table 5.5.  
 
Analysis of cell cycle regulators mRNA expression by RT-PCR analysis (Figure 2.4) showed 
reduced P53 mRNA levels in all the cancer cell lines compared to immortalized keratinocytes 
HaCaT cells. P21 gene transcript was significantly high expressed in all oesophageal cancer cell 
lines; KYSE30 and WHCO1 but reduced in CT1, Hela and MDA-231 cells. Due to the 
observations and conclusion on the effects of BCLAF1 deficiency on the expression of P53 and 
P21, i.e., knocking down BCLAF1 attenuated P53 expression both at RNA and protein levels, and 
slightly upregulated P21 mRNA and protein levels. Comparing the ratio of P53/P21 levels in the 
immortalized cells versus the cancer cell lines, one could conclude on the results in Figure 2.4, 
that the deficiency BCLAF1 levels in the cancer cell lines contributed to the attenuated P53 levels 
and upregulation of P21 expression. 
2.2.3 Cell cycle analysis  
Given the involvement of BCLAF1 in P53 transcription activation and in the γH2AX-mediated 
regulation of P53/P21 expression and cell cycle progression (Liu et al., 2007; Lee, Yu, et al., 
2012). Flow cytometric analysis was conducted to assess the cell cycle flow of the cell lines. 




Figure 2.5. Flow cytometry analysis of the cell lines cell cycle progression. Flow cytometry analysis of 
CCD1068SK, HaCaT, MDA-231, KYSE30 and WHCO1 cells was carried out as described in Material and Methods. 
Cells were stained with propidium iodide (PI) and analysed using a FACScan cell sorter. A); Each cell line was 
conducted in triplicate and 20 000 events were captured. B); The bar graphs showed the relative quantity of G1, S, G2 
and Apoptotic cells population in the five cell lines analysed. 
 
Cell cycle progression of CCD1068SK, HaCaT, MDA-231, KYSE30 and WHCO1 cells was 
conducted by flow cytometry analysis (Figure 2.5). MDA-231 cells showed higher cell population 
of the S-phase, slightly reduced G1 cell population and more apoptotic cells compared to the other 











Several genetic variations in the human genome are known to play a significant role in 
tumourigenesis. Chromosomal translocations, loss of heterozygosity, insertions and deletions are 
some of the large scale mutational events in the DNA sequence of a gene (Talseth-Palmer & Scott, 
2011). Whole genome sequencing studies of oesophageal cancer biopsies  have shown BCLAF1 
aberrations in oesophageal cancer (Mwapagha, 2014). 
Although BCLAF1 deletions have been observed in a number tumour types, very little is known 
about BCLAF1 expression patterns in human cancers or in cancer cell lines.  In addition, several 
BCLAF1 splice variants have been identified and have been observed to be differently expressed 
in different tumour types (Kasof et al., 1999; Zhou et al., 2014). This study examined at the 
expression patterns of BCLAF1 in different human transformed and cancer cell lines as well as 
genes linked to BCLAF1. 
BCLAF1 was found to be expressed in low levels in all cancer cell lines and at extremely low 
levels in MDA-231 and WHCO1 cells. Even though mutant BCLAF1 is not associated with breast 
cancer, low BCLAF1 mRNA levels observed in the triple-negative breast cancer MDA-231 cells 
might contribute to the tumour development or better yet contribute to the classification and 
treatment of the breast cancer tumours in triple negative breast cancer. BCLAF1 is a restriction 
factor of oncogenic-human cytomegalovirus (HCMV). Elevated expression of BCLAF1 inhibits 
HCMV replication, and, hence suppressing and preventing HCMV infection. Moreover, BCLAF1 
steady-state protein levels are degraded by HCMV immediately following its infection through 
two temporally independent mechanisms identified by (Lee, Kalejta, et al., 2012) work. HCMV 
targets a number of  different cell types, including, epithelial cells, endothelial cells, fibroblasts, 
stromal cells, and hepatocytes (Herbein & Kumar, 2014). Although HCMV has been detected in 
breast cancer tissues, there does not appear to be any significant link between HCMV infection 
and breast cancer progression (Utrera-Barillas et al., 2013). However, a significant increase in 
HCMV expression is one of the biomarkers of inflammatory breast cancer (El-Shinawi et al., 
2013). In the past decade, HCMV genome and antigens has been detected in various human 
cancers, including breast cancer, prostate cancer, brain cancer, colon cancer, gastric cancer and 
salivary gland cancer (Michaelis et al., 2009; Soroceanu & Cobbs, 2011; Jin et al., 2014). HCMV 
infection is not rare in oesophageal cancer patients, who have undergone stem cell transplantation 
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or receiving immunosuppressant agents or have human immunodeficiency virus (HIV) infection 
(Umemoto et al., 2016). In these patients, HCMV has been shown to remain inactive but 
reactivation of the virus can occur during chemoradiotherapy and may affect  the prognosis of the 
patients, moreover, reactivation of HCMV during chemoradiotherapy is associated with 
development of cytomegalovirus esophagitis  in these patients (Chang et al., 1992; Aizawa et al., 
2017). HCMV infection in cancer contributes to BCLAF1 protein degradation which results in 
reduced BCLAF1 levels in breast cancer. In HeLa cells, overexpression of BCLAF1 induces 
apoptosis (Kasof et al., 1999). Overexpression of BCLAF1 is suppressed by co-expression of 
BCL2 and BCL-XL proteins. Anti-apoptotic BCL2 and BCL-XL mRNA levels is low in HeLa 
cells, hence overexpression of BCLAF1 was observed in this study.  
An investigation of BCLAF1-related gene expression in the same cell lines revealed extremely low 
levels of proapoptotic gene expression (Caspase-3, Caspase-9 and BAX) in the MDA-231 cell line 
compared to other cell lines.  The same was true for the DNA damage repair genes H2AX, BACH1, 
BRCA1 and mostly, the EXO1, ATRIP genes. Deregulation of proapoptotic genes results in the 
disruption of the regulation of the balance between proliferation and apoptosis and it is one of the 
most important traits of malignancy (Marx & Meden, 2001). BCLAF1 is involved in the induction 
of Caspase-3, Caspase-9 and BAX apoptotic activity and its deficiency in cells reduces mRNA 
and protein expression of these genes (Kasof et al., 1999; Lee, Yu, et al., 2012). Thus, reduced 
transcript levels of Caspase-3, Caspase-9 and BAX were observed in all cell lines but extremely 
low in the MDA-231 cells. Apoptosis inhibitors such as  BCL2 related proteins are known to be 
over expressed in various tumours, such as epithelial tumours and human B-cell lymphoma and 
they play an important role in tumourigenesis and progression by inhibiting cell death and 
prolonging the survival of malignant cells (Tsujimoto et al., 1985; Marx et al., 1997; Yip & Reed, 
2008). BCL2 was observed to be slightly expressed in the MDA-231 cells, over expression of 
BCL2 downregulates proapoptotic BAX expression (Dagmar Marx & Meden, 2001), hence BAX 
reduced levels observations in the cell lines 
BRCA1 is present in low levels or absent in most breast cancers (Garcia et al., 2011) and its low 
expression predispose women to breast cancer (Welcsh & King, 2001). EXO1 and ATRIP are some 
of the genes regulated by the BRCA1/BCLAF1 mRNA splicing complex, and the stability and 
efficient production of their transcripts depends on the activity of the BRCA1/BCLAF1 mRNA 
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splicing complex (Savage et al., 2014). Furthermore, deregulation or loss of BRCA1 or BCLAF1 
results in loss of BRCA1/BCLAF1-mediated mRNA splicing activity, hence, ectopic expression 
of ATRIP, BACH1, and EXO1  (Savage et al., 2014). As expected, ATRIP and EXO1 transcript 
levels were reduced in the all cell lines analysed and extremely low levels in MDA-231 cells that 
have extremely low expression of BCLAF1 and BRCA1. 
Another important feature of BCLAF1 is its involvement in the regulation of γH2AX-mediated 
repair of DNA damage associated with either apoptosis or double strand breaks during DNA 
damage. In irradiated-responsive cells, BCLAF1 translocate to the nuclear envelope and merges 
with γH2AX, a novel biomarker for DNA double-strand breaks, which in turn stabilizes the 
Ku70/DNA-PKcs complex involved in facilitating non-homologous end joining double strand 
break repair (Lee, Yu, et al., 2012). We investigated the expression of H2AX and BAX-cytoplasmic 
interacting partner, Ku70 in several cell lines. In HeLa and MDA-231 cells both H2AX and Ku70 
gene expression were strongly repressed compared to the other cell lines. Deregulation of BCLAF1 
and H2AX affect Ku70/DNA-PKcs complex stability in the nucleus and reduces the association 
between Ku70 and DNA-PKcs. Furthermore, it results in reduced Ku70 nucleonic levels whilst 
enhancing its translocation to the cytoplasm. In the cytosol, the binding of Ku70 to BAX is 
enhanced, resulting in inactivate BAX. Previous studies have also reported that BCLAF1 is 
required to release BAX from the anti-apoptotic Ku70-BAX complex (Lee, Yu, et al., 2012). In 
MDA-231 cells, H2AX transcript levels were extremely low compared to other cell lines, we thus 
hypothesise that H2AX is a BCLAF1 downstream gene. In contrast, in vitro studies have shown 
that BCL-2 interacts with BCLAF1 (Kasof et al., 1999)  to negatively regulate  BCLAF1 double 
strand break  repair activity by disrupting the Ku70/DNA-PKcs complex (Downs & Jackson, 2004; 
Lee, Yu, et al., 2012). Moreover, depletion of BCL-2 enhances the DNA binding activity of the 
Ku70/DNA-PKcs complex accelerating DNA repair (Wang et al., 2008). 
The pathway of the key cell cycle  regulator, P53, is inactivated in the most human tumours 
(Herrero et al., 2016). In this study, P53 which is positively regulated by BCLAF1 through the 
CPE-TP53 element in a PKCδ-dependent manner (Liu et al., 2007) was observed to be 
significantly reduced in all the cancer cell lines. In addition, previous work on siRNA-mediated 
BCLAF1 knockdown studies indicated that BCLAF1 deficiency significantly attenuates P53 
mRNA levels, leading to a reduction of P53-dependent apoptosis activity (Liu et al., 2007). 
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Depending on the severity of DNA damage, P53 determines the cell fate through activation of 
different pathways (Luo et al., 2017). The cyclin-dependent kinase inhibitor P21 and pro-apoptotic 
genes such as BAX,  are some of the P53 target genes (Luo et al., 2017). Deregulation of P21 
results in cell cycle deregulation and uncontrolled cell growth (Elbendary et al., 1996). The over-
expression of P21 in oesophageal cancer cell lines; KYSE30 and WHCO1 results in P21-
dependent cell cycle arrest at G1 phase. 
Cell cycle analysis by flow cytometry indicated that MDA-231 cells have a distinct profile, with 
more cells in the S-phase and less in the G1 phase and more apoptotic cells compared to the other 
cell lines. Although BCLAF1- and P53-mediated apoptosis pathways are deregulated in the MDA-
231 cells, due to the low levels expressions, the presence of excessive apoptotic cells could be due 
to activation of extrinsic apoptotic pathway, initiated by the interaction of exposed cell surface 
death receptors, belonging to the superfamily of tumour necrosis factor receptors (TNFR) 
(Guicciardi & Gores, 2009). The downstream effect of the initiation of the extrinsic apoptotic 
pathway induces the activation of initiator pro-caspase-8 and/or Caspase-10 resulting in the 
formation of the death-inducing signalling complex (DISC), which triggers the processing of the 
downstream effectors such as Caspases-3, Caspase-6 and Caspase-7 whose activation leads to the 
cleavage of critical cellular  substrates, inducing cell death (Degterev et al., 2003). 
Taken together, the data suggests that BCLAF1 expression in different cell types is influenced by 
various factors, depending on the cause(s) and development of cancer. This study suggests that 
deregulation and differential expression of BCLAF1 and of BCLAF1-associated genes in the cell 
lines could result in dysfunctional regulation of signalling pathways such as apoptosis, DNA 
damage repair and cell cycle which play critical roles in development and progression of cancer. 
The downstream effects of BCLAF1 knockdown and its molecular role in tumourigenesis is 








The downstream effects after BCLAF1 knockdown and knockout 
3.1 Introduction 
The use of RNA interference (RNAi) technology is a very potent tool in the modification of gene 
expression. Furthermore, it is used for investigating the stimulatory or suppressive role of a given 
gene in biological pathways, to validate gene function, its relation to the disease phenotypes and 
as a tool for gene therapy in cancer and other genetic diseases (Guo et al., 2013; Kaufmann et al., 
2013; Barrangou et al., 2015). Several studies   using   RNAi technology have suggested a 
functional role for BCLAF1 functional in several cancer signalling pathways, consistent with the 
hallmarks of cancer (McPherson et al., 2009; Sarras et al., 2010; Lee, Yu, et al., 2012; Sarras, 
2012; Zhou et al., 2014; Shao et al., 2016; Vohhodina et al., 2017). 
BCLAF1 was originally identified in a yeast two-hybrid screen of proteins that interact with E1B 
19K. E1B-19k is one of the two proteins encoded by the E1B gene of the adenovirus, which blocks 
P53-independent apoptosis mechanism in adenovirus-infected cells (White & Cipriani, 1990; 
Lowe & Ruley, 1993; White, 2001). Subsequent studies indicated BCLAF1 as a protein-protein 
interacting partner with BCL2 family members  and its overexpression induced apoptosis in HeLa 
cells and suppresses transformation by adenovirus E1A and E1B-19K proteins or mutant P53 
(Kasof et al., 1999). McPherson and his colleagues used in-vivo knockdown studies of BCLAF1 
to confirm the role of BCLAF1 in the cell death signalling pathway, and in proper lung 
development, T-cell activation and immune system homeostasis in BCLAF1 knockout mice 
(McPherson et al., 2009). Furthermore, BCLAF1 deficiency by siRNA caused cell resistance to 
ceramide-induced apoptosis, whereas overexpression of BCLAF1 induced the upregulation of P53 
and BAX levels, but down-regulating MDM2 levels (Sarras et al., 2010). Studies using siRNA-
mediated knockdown identified further roles for BCLAF1 in other process such DNA damage 
repair, mRNA splicing and stabilization of transcripts, suggesting that BCLAF1 is a tumour 
suppressor (Lee, Yu, et al., 2012; Savage et al., 2014). 
The work in this chapter was designed provide some insight into the contribution of BCLAF1 in 
tumourigenesis by examining the effects of BCLAF1 deficiency in signalling pathways such as 




3.2.1 siRNA-mediated BCLAF1 knockdown  
Transformed human lung fibroblasts CT1 cells were used as a model to study and identify the 
effects of downstream effects of BCLAF1 knockdown and its contribution in tumorigenesis. CT1 
cells were treated with BCLAF1 siRNA. BCLAF1 knockdown was validated at both the protein 
and RNA level 24 hours post transfection (figure 3.1). 
 
Figure 3.1. siRNA-mediated BCLAF1 knockdown. CT-1 cells were treated with either scrambled siRNA as 
negative control or BCLAF1 siRNA. RNA and protein extracts were harvested from the cells 24 hours post-
transfection. A); BCLAF1 mRNA was quantitated using specific primers as indicated in Material and Methods in 
Table 5.5. B); Protein extracts were electrophoresed on a 10% polyacrylamide SDS gel, transferred to nitrocellulose 
membranes and probed for BCLAF1 protein using an anti-BCLAF1 antibody. The gels were stripped and probed with 
an anti-GAPDH antibody to serve as a loading control.   
 
Analysis of BCLAF1 mRNA by RT-PCR analysis in control siRNA and BCLAF1 siRNA treated 
cells (Figure 3.1A) showed that the siRNA successfully knocked down BCLAF1 mRNA levels by 
at least 50% compared to the untreated or control non-specific scrambled siRNA. Western blot 
analysis confirmed that the BCLAF1 protein level was also significantly reduced in the BCLAF1 
siRNA treated cells (Figure 3.1B). Previous in vitro studies on BCLAF1 knockdown achieved a 
60-30% BCLAF1 knockdown (Lee, Yu, et al., 2012; Savage et al., 2014). 
3.2.2 The effect of BCLAF1 on cellular gene expression 
To assess whether the expression of genes downstream of BCLAF1 was altered by the targeted 
disruption of BCLAF1 expression, RNA and protein extracts from either non-specific scrambled 
control siRNA, BCLAF1 siRNA and untreated cells were collected 24 hours post-transfection. RT-
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PCR and western blot analyses were carried out to determine the effects of BCLAF1 deficiency on 
proapoptotic, anti-apoptotic, DDR gene expression and cell cycle regulators. 
 
Figure 3.2. The effect of BCLAF1 knockdown on proapoptotic gene expression. RNA and protein extracts were 
prepared from CT1 cells 24 hours post-transfection with either control siRNA or BCLAF1 siRNA as described in 
Material and Methods. A); RT-PCR analysis of the proapoptotic genes BAX, Caspase-3 and Caspase-9 mRNA 
expression was quantitated using specific primers as indicated in Material in Table 5.5. B); Western blot analysis of 
BAX, Caspase-3 and Caspase-9 proteins in BCLAF1 siRNA-treated cells. GAPDH was used as a loading control. 
This experiment was done in triplicates.  
 
The data in (Figure 3.2A) and (Figure 3.2B) showed that knockdown of BCLAF1 expression had 
a significant effect on the expression of the apoptotic genes and downregulated BAX expression 










Figure 3.3. The effect of BCLAF1 knockdown on anti-apoptotic gene expression. RNA and protein extracts were 
prepared from CT1 cells 24 hours post-transfection with either control siRNA or BCLAF1 siRNA as described in 
Material and Methods. A); RT-PCR analysis of the antiapoptotic genes BCL2 and BCL-XL. B); Western blot analysis 
of BCL2 protein in BCLAF1 siRNA-treated cells. GAPDH was used as a loading control. This experiment was done 
in triplicates. BCL-XL antibody suitable for western blot was not commercially available. 
 
Analysis of antiapoptotic mRNA expression by RT-PCR analysis showed no significant effect in 
the BCL2 expression both at RNA and protein levels as well as BCL-XL mRNA expression (Figure 
3.3). 
 
Figure 3.4. The effect of BCLAF1 knockdown on DDR gene expression. RNA and protein extracts were prepared 
from CT1 cells 24 hours post-transfection with either control siRNA or BCLAF1 siRNA as described in Material and 
Methods. A); RT-PCR analysis of the DDR genes using specific primers as indicated in Material and Methods in 
Table 5.5. B); Western blot analysis of DDR protein in BCLAF1 siRNA-treated cells. GAPDH was used as a loading 
control. This experiment was done in triplicates. ATRIP, BACH1 and Ku70 antibodies suitable for western blot were 




Depletion of BCLAF1 results in reduced mRNA levels of EXO1, ATRIP and BACH1 (Figure 
3.4A). BCLAF1 knockdown attenuated EXO1 and H2AX protein levels (Figure 3.4B). 
 
Figure 3.5. BCLAF1 knockdown effects on cell cycle regulators. RNA and protein extracts were prepared from 
CT1 cells 24 hours post-transfection with either control siRNA or BCLAF1 siRNA as described in Material and 
Methods. A); RT-PCR analysis of the cell cycle regulator P53 and P21. B); Western blot analysis of P53 and P21 
protein in BCLAF1 siRNA-treated cells. GAPDH was used as a loading control.  
 
Knocking down BCLAF1 attenuated P53 expression both at RNA and protein levels, and slightly 
upregulated P21 mRNA and protein levels (Figure 3.5). 
3.2.3 BCLAF1 knockdown effects on cell cycle and apoptosis 
BCLAF1 is previously reported to be involved in P53 transcription activation and in the γH2AX-
mediated regulation of P53/P21 expression and cell cycle progression (H. Liu et al., 2007; Y. Y. 
Lee et al., 2012), meanwhile, BCLAF1 knockdown altered the expression of cell cycle regulators 
by downregulating P53 expression and upregulating P21. The effects of BCLAF1 knockdown on 
cell cycle progression was determine by flow cytometric analysis CT1 cell transfected with either 





Figure 3.6.  BCLAF1 knockdown on the cell cycle progression. CT1 cells were transfected with either control 
siRNA or BCLAF1 siRNA. Cells were stained with PI and analysed using a FACScan-cell sorter. Each sample was 
analysed in triplicate and 20 000 events were captured. A); BCLAF1 knockdown was validated using specific primers 
as indicated in Material and Methods in Table 5.5. B); BCLAF1 knockdown effects on cell cycle flow. C); The bar 
graphs showed the relative quantity of G1, S, G2 and apoptosis population in the CT1 BCLAF1 siRNA transfected 
cells compared to the untreated and control siRNA. 
 
Analysis of BCLAF1 mRNA by RT-PCR analysis in control siRNA and BCLAF1 siRNA treated 
cells showed that the siRNA successfully knockdown BCLAF1 mRNA levels by more than 50% 
compared to the untreated or control non-specific scrambled siRNA (Figure 3.6A). BCLAF1 
knockdown reduced levels of apoptotic cells and a slightly accumulation of cells in the G1 phase  





Figure 3.7. Effects of BCLAF1 knockdown on apoptosis. CT1 cells were transfected with either control siRNA or 
BCLAF1 siRNA. Cells were stained with PI and Annexin V and analysed using a FACScan-cell sorter. Each sample 
was analysed in triplicate and 20 000 events were captured. A); 24 hours post transfection, BCLAF1 knockdown was 
validated using specific primers as indicated in Material and Methods in Table 5.5. B); Single stain positive controls; 
CT1 cells were either stained with PI only, Annexin V stain only or unstained. C); FITC Annexin V/PI double staining 
of cells.  
 
Analysis of BCLAF1 knockdown mRNA by RT-PCR analysis in control siRNA and BCLAF1 
siRNA treated cells showed that the siRNA successfully knocked down BCLAF1 mRNA levels by 
about 75% compared to the untreated or control non-specific scrambled siRNA (Figure 3.7A). 
Viable cells are FITC Annexin V and PI negative are in the lower left quadrant; cells that are in 
early apoptosis are FITC Annexin V positive and PI negative, in the lower right quadrant; and cells 
that are in late apoptosis or already dead are both FITC Annexin V and PI positive in the upper 
right quadrant (Figure 3.7B). BCLAF1 knockdown reduced dead cells population in BCLAF1 
siRNA treated cells with a population of 2.55% compared to untreated and control siRNA cells 
with a dead population of 4.11% and 3.57% respectively (Figure 3.7C). 
3.2.4 The effect of BCLAF1 on DNA damage and Repair  
In order to determine whether BCLAF1 promotes resistance to DNA damage, we examined the 
effect of BCLAF1 depletion on cellular survival after UV induced DNA damage. The optimum 
ultraviolet (UV) dose based on cell survival was determined 24 hours post UV induced DNA 
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damage. UV exposure dosages were 0J/M2, 40J/M2, 200J/M2 and 500J/M2. DNA was extracted 
electrophoresed on a 1% agarose gel to visualise DNA fragmentation. 
3.2.4.1 UV radiation induce DNA damage and cell survival 
 
 
 Figure 3.8. UV induced DNA damage and cell survival. 2.0x105 CT1 cells/well were seeded on 6-well plates and 
left to attach and grow overnight.  Cells were treated with UV light at the indicated doses and let to recover for 24 
hours. A); Cell morphology changes were observed by microscopy in cells. B); DNA electrophoretic profiles analysed 
on a 1% agarose gel. MW, DNA size marker. Each experiment was performed three independent times. 
 
The results in (Figure 3.8A) showed the presence of morphological changes such as cell shrinkage 
in cells exposed at 200 and 500 J/M2, 80-90% of the population died compared with unexposed 
cells, while cells exposed to 40J/M2 morphologies remained the same and cells were able to 
recover and survived 24 hours post UV treatment. DNA degradation was observed in all the cells 







Figure 3.9. Recovery of cells after UV irradiation. CT1 cells were treated with 40 J/M2 UV light and left to recover 
for either 0.5, 1, 5 or 24 hours. At each time point, the number of surviving cells were observed under a microscope 
and compared to the untreated control. Cell viability decreased dependent on recovery time point.  
The results in (Figure 3.9) showed that depending on the recovery time given and if the extent of 
DNA damage exceeds the capacity of repair mechanisms, cells go through apoptosis. About 20-




Figure 3.10 The effect of UV radiation on the cell survival and apoptosis. CT1 cells were treated with 40 J/M2 UV 
light and left to recover for either 0.5, 1, 5 or 24 hours. At each time point cells were stained with PI and Annexin V 
and analysed using a FACScan-cell sorter. Each sample was conducted in triplicate and 20 000 events were captured. 
A); Single stain positive controls; CT1 cells were either stained with PI only, Annexin V stain only or unstained. B); 
FITC Annexin V/PI double staining of cells. 
The data in (Figure 3.10) showed that untreated cells (No UV) and UV treated cells with 0 hours 
recovery time (UV+0 recovery time) were primarily FITC Annexin V and PI negative i.e. more 
viable cells. Early apoptotic cell population i.e. Annexin V-positive but PI-negative cells increased 
in a recovery time-dependent manner (cells with 0.5, 1-hour recovery time). Cells that are left for 
24 hours to recover had a high population of the early apoptotic cells so as dead cells population 
with 23.33% and 14.07% respectively, and less viable cells population compared to untreated cells. 
3.2.4.2 BCLAF1 knockdown effects in DDR  
To examine the ability of BCLAF1-depleted cells to recruit γ-H2AX to damaged DNA sites for 
effective DNA repair, a time-course and cell survival test was carried out to determine the optimal 
time-course selection dependent on the survival of cells and sustained cell morphology post UV 
exposure see (Figure 3.9) and (Figure 3.10).  After 24 hours, BCLAF1 siRNA-transfection cells 
and untreated cells were exposed to 40J/M2 UV dose for immunofluorescence analysis. BCLAF1 




 Figure 3.11 BCLAF1 knockdown validation. Representative immunofluorescent staining of BCLAF1. 2.0x105 CT1 
cells/well were seeded on cover slips in 6-well plates overnight. 24 hours post BCLAF1 siRNA transfection as 
described in Materials and Methods, cells were fixed and stained for BCLAF1. Left: nuclear staining with DAPI; 
Middle: cell nucleus as well as cytoplasm incubated with anti-BCLAF1 antibody; Right: merged image of BCLAF1 
and DAPI staining. The red arrows indicate the localization of BCLAF1. Images were obtained at 400x.  
 
Analysis of BCLAF1 expression in untreated and BCLAF1 siRNA treated cells showed a decrease 
in the cytoplasmic and nuclear BCLAF1 expression in BCLAF1 siRNA treated cells compared to 






Figure 3.12 Damaged DNA repair in CT1 cells post UV exposure. Representative immunofluorescent staining of 
γ-H2AX marked DNA damage in CT1 no siRNA-40 J/M2 UV-treated cells and 0, 2.5 and 5 hours recovery time. Cells 
were fixed and stained for γ-H2AX as described in Materials and Methods. Top row: nuclear staining with DAPI; 
Middle: cell nucleus as well as cytoplasm incubated with anti-γH2AX antibody; bottom row: merged image of γH2AX 
and DAPI staining. The red arrows indicate the localization of γ-H2AX-damaged DNA marked sites. Images were 
obtained at 400x. Each time point was performed in triplicate. 
 
 
Figure 3.13 BCLAF1 mediates Resistance to DNA damage and is required for efficient DNA repair. 
Representative immunofluorescent staining of γ-H2AX marked DNA damage in CT1 siRNA-mediated BCLAF1 
depleted 40J/M2 UV-treated cells and 0, 2.5 and 5 hours recovery time. Cells were fixed and stained for γ-H2AX as 
described in Materials and Methods. Top row: nuclear staining with DAPI; Middle: cell nucleus as well as cytoplasm 
incubated with anti-γH2AX antibody; Bottom row: merged image of γH2AX and DAPI staining. The red arrows 
indicate the localization of γ-H2AX-damaged DNA marked sites. Images were obtained at 400x. Each time point was 
performed in triplicate. 
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Results in (Figure 3.12 and Figure 3.13) showed that BCLAF1-depleted CT1 cells showed a 
significant defect in their ability to resolve γ-H2AX-marked damaged DNA sites 5 hours after UV 
treatment. These cells displayed an increase in damaged DNA sites in comparison to untreated 
cells, indicating that loss of BCLAF1 results in reduced γH2AX repair activities and an increased 
in defective DNA repair and genomic instability following DNA damage.  
3.2.5 CRISPR/Cas9-mediated BCLAF1 knockout 
In order to get complete knockout of BCLAF1 expression, CRISPR/Cas9-mediated BCLAF1 
knockout was carried out. Three samples were set up, untreated, Cas9 only control and co-
transfection with Cas9 nuclease expression plasmid and two distinct BCLAF1 guide RNAs 
(gRNAs) (Table 3.1). The two gRNAs targeted BCLAF1 exon 4 and exon 7, thereby silencing 
BCLAF1 and establishing a BCLAF1 knockout cell line. Enrichment of the mKate-Cas9 expressing 
cells was done by fluorescence-activated cell sorting (FACS) analysis 72 hours post-transfection, 
to increase the frequencies of cells with Cas9-induced gene engineering events. Two months post 
clone selection and expansion, RNA and protein extracts were harvested from cells with either 
mKate2-Cas9 nuclease expressing plasmid only or mKate2-Cas9 nuclease expression plasmid and 
BCLAF1 gRNAs and untreated cells for CRISPR/Cas9-mediated BCLAF1 mutational analysis and 
examine the downstream effect of BCLAF1 deletion in tumourigenesis. 
3.2.5.1 CRISPR/Cas 9 transfection on CT1 cell line 
Table 3.1 BCLAF1 knockout sample set up. Three samples were prepared; untreated control 
sample (cell viability), Cas9-expressing plasmid only control sample (Negative control) and Cas9-






Figure 3.14 FACS plots analysis of CT1 cells post-transfection. 1x105 cells were seeded on 24-well plates 
overnight, 72 hours post-transfection with either Cas9 plasmid only or Cas9 plasmid+ tracrRNA + two BCLAF1 
gRNAs and the untreated cells were FAC-sorted using FACSDiva Version 6.1.3, depending on the expression of the 
mKate2 chromophore of an excitation maximum of 588 nm and emission maximum of 633 nm. mKate2-expressing 
cells of Cas9 only and CRISPR/Cas9-mediated BCLAF1 knockout cells were drop-pooled in a 6-well plate.  
Data in (Figure 3.14) showed that both Cas9-expressing control and BCLAF1 knockout cells 
showed a positive population of mKate2-Cas9 expressing cells compared to untreated cells which 
showed no frequency of mKate2-Cas9 positive cells in quantrant 4 (Q4). 
 
Figure 3.15 Expression of mKate2 in CT1- Cas9 only treated cells. Two weeks post clone selection and expansion, 
negative control Cas9 only cells and untreated cells were observed and photographed under fluorescence microscope 
for mKate2 expression, a monomeric far-red fluorescent protein.  
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CT1-Cas9 cells expressed mKate2, substantial decrease in mKate2 expression was observed three-
four weeks later this is associated with increasing passage number. BCLAF1 knockout treated cells 
were not used for imaging in avoidance of contamination (Figure 3.15). 
3.2.5.2 BCLAF1 knockout validation 
In order to assess whether the knockout of BCLAF1 has the same effects on BCLAF1 downstream 
genes expression and in tumourigenesis as the knockdown of BCLAF1. Western blot analysis was 
carried out to validate the knockout of BCLAF1. 
 
Figure 3.16 CRISPR/Cas9-mediated BCLAF1 knockout validation. Protein extracts were prepared from CT1 cells 
with either Cas9 nuclease expressing plasmid only, BCLAF1 knockout and untreated cells as described in Material 
and Methods. GAPDH was used as a loading control. 
Analysis of BCLAF1 protein expression in untransfected cells, Cas9 only transfected and BCLAF1 
knockout cells by western blot analysis (Figure 3.16) showed that CRISPR/Cas9-mediated 
BCLAF1 knockout upregulated BCLAF1 protein levels. 
3.2.5.3 CRISPR/Cas9-mediated BCLAF1 knockout mutational analysis 
To clarify the absence of BCLAF1 deletion but over-expression of BCLAF1 in CRISPR/Cas9-
mediated BCLAF1 knockout, mutational analysis of BCLAF1 wild type (untreated cells) and 
BCLAF1 knockout cells was done. With the knowledge of where the BCLAF1 gRNAs targeted 
(exon 4 and exon 7), two PCR primer sets were designed, (primer set 1 and primer set 2) each set 
comprised of a forward and a reverse primer targeting regions flanking the targeted regions, 
upstream and downstream of exon 4 and exon 7 respectively (Figure 3.18). RNA extracts from 
either BCLAF1 wild type and BCLAF1 knockout cells was used to synthesize cDNA and then used 
as a template to amplify the BCLAF1 targeted regions by polymerase chain reaction (PCR). The 




Figure 3.17 PCR primer design. Two sets of primers were designed in silico, primer set 1 (highlighted in yellow) 
and primer set 2 (highlighted in green) targeting exon 4 and exon 7 (red font) respectively. BCLAF1 gRNAs 
highlighted in olive green. Each primer set comprised of a forward and a reverse primer, upstream and downstream 
targeted regions.  
 
Figure 3.18 Agarose gel electrophoresis characterization of the BCLAF1 amplified regions. Multiplex-PCR 
amplification products of the targeted regions of BCLAF1 wild type and BCLAF1 knockout cDNA using the primers 
described in the Materials and Methods table 4.1 were analysed on 1% agarose gel. mw: molecular weight marker. 
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Lane f1+r1 (primer set 1) product size is 1176 bp, lane f2+r2 (primer set 2) product size 1877bp and lane f1+r2 (primer 
set 1-forward primer + primer set 2-reverse primer) product size is 2999 bp.  
Electrophoresis analysis of the multiplex-PCR products (Figure 3.18) showed the presence of the 
shorter, fainter band (900bp) heterozygous deletion in the exon 4 was observed in the BCLAF1 
KO sample; (f1 + r1 lane), pointed with the red arrow, but not in BCLAF1 wild type sample. The 
CRISPR/Cas9-mediated BCLAF1 knockout didn’t work, hence, further analysis on the effects of 





















A tumour cell may contain many point mutations and various structural variants. The point 
mutations and structural variants such as insertions and deletions, translocations and copy number 
changes, loss of heterozygosity are few of the genetic alterations that are acquired during cancer 
progression (Albertson et al., 2003; Popova et al., 2009). Several genetic alterations disrupt the 
normal balance during cell proliferation, survival and differentiation and result in loss of control 
of cellular transformation (Hahn et al., 1999; Mitelman et al., 2007). Understanding the genetics 
mechanisms of cancer contribute to identification of new cancer genes, tumour classification and 
cancer genome analysis (Garraway & Lander, 2013; Liu et al., 2015).  
BCLAF1 aberrant events have been observed in various tumours and its deficiency has been 
associated with tumour development (Kasof et al., 1999; Mwapagha, 2014).  BCLAF1 plays a key 
role in several cellular pathways, including apoptosis, RNA splicing, transcriptional regulation, 
DNA damage response, lung development and T-cell activation (Kasof et al., 1999; McPherson et 
al., 2009; Sarras et al., 2010; Lee, Yu, et al., 2012; Sarras, 2012; Savage et al., 2014). BCLAF1 
was originally identified as a proapoptotic and repressor of transcription through an interaction of 
anti-apoptotic bcl2 family members (Kasof et al., 1999). Several subsequent studies have 
elaborated more extensively on the role of BCLAF1 in regulation of apoptotic genes and induction 
of apoptosis (Sarras et al., 2010; Lee, Yu, et al., 2012). Since BCLAF1 is involved γH2AX-
mediated DNA repair and RNA splicing and transcript stabilization of genes involved in DDR 
pathways it is suggested that BCLAF1 is a tumour suppressor (Lee, Yu, et al., 2012; Savage et al., 
2014).  
Here we used siRNA mediated gene knockdown studies to identify the contribution of BCLAF1 
to tumourigenesis, by examining the effects of BCLAF1 deficiency in signalling pathways such as 
apoptosis, DDR and cell cycle. This study identified H2AX as a downstream gene of BCLAF1 and 
its deficiency by siRNA downregulates H2AX protein expression. 
We examined the downstream effects of BCLAF1 deficiency on apoptotic genes. Our study 
indicated that BCLAF1 deficiency downregulates the expression of proapoptotic BAX and 
Caspase-3 but not Caspase-9 in human fibroblast CT1 cells. These findings are consistent with a 
role for BCLAF1 in cell death signalling, highlighted in the studies by (Kasof et al., 1999; 
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McPherson et al., 2009; Lee, Yu, et al., 2012) that BCLAF1 is a death promoting protein and 
overexpression of BCLAF1 induces apoptosis.  
P53 is a major regulator of cell growth, apoptosis and dictates cell fate, depending on the severity 
of DNA damage. In the G1 phase cell cycle arrest, P53 triggers transcription of P21(cip1/waf1) a key 
component in cell cycle regulation (Kruse & Gu, 2009). BCLAF1 has long been shown to be 
involved in the transcription of P53 by interacting with CPE-TP53 during DNA damage (Liu et 
al., 2007), furthermore, (Lee, Yu, et al., 2012) suggested a role of BCLAF1 in P21 regulation, and 
its deficiency upregulates P21 expression. Our studies confirmed that knocking down BCLAF1 
significantly upregulates P21 expression and attenuates P53 expression, which leads to a P21-
dependent G1 phase cell cycle arrest. Moreover, BCLAF1 knockdown reduced apoptotic cells in 
the cell cycle flow, in agreement with our results on BCLAF1 deficiency and downregulation of 
Caspase-3 and BAX protein levels. 
In addition to the  role of BCLAF1 in DDR, (Savage et al., 2014) also suggested BCLAF1 as a key 
component of a DNA damage induced-BRCA1 protein complex that regulates pre-mRNA splicing 
of various of genes including EXO1, ATRIP and BACH1. These genes are involved in DNA 
damage signalling and repair, promoting the genomic stability (Caestecker & Van de Walle, 2013). 
Consistent with the role of BCLAF1 in mRNA splicing, we observed significant effects of BCLAF1 
deficiency on EXO1, ATRIP, and BACH1 mRNA transcripts in human fibroblast CT1 cells, and 
our results confirmed that BCLAF1 is indeed required for EXO1, ATRIP and BACH1 mRNA 
stabilization and efficient production of transcripts, and that abrogation of BCLAF1 reduced the 
expression of these genes. We have also examined DNA repair dynamics in BCLAF1-depleted 
CT1 cells following DNA damage, previously highlighted by (Lee, Yu, et al., 2012; Savage et al., 
2014) studies,  our study supports these findings and shows that BCLAF1 depleted cells showed a 
significant defect in their ability to resolve γH2AX-marked DNA lesions 5 hours post UV 
treatment, which is consistent with our finds of BCLAF1 knockdown downregulation of H2AX 
protein levels, hence less activity of γH2AX induced DNA repair 5 hours post irradiation resulting 
in an increased DNA lesions compared to control cells.  
Although (Savage et al., 2014) findings suggested that BCLAF1 depleted cells exhibited defect in 
their ability to rectify γH2AX-marked DNA breaks 24 hours post irradiation, they supported their 
findings to BCLAF1 role in BRCA1/BCLAF1 mRNA splicing complex, involved in mRNA 
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splicing and stabilization of genes required for DNA repair and maintenance of genomic stability. 
In addition, our studies suggested that the downregulation of H2AX in BCLAF1 depleted cells 
contributes to their inability to resolve γH2AX-marked DNA lesions, hence elevated defective 
DNA repair in BCLAF1 depleted cells in comparison to control cells. 
Taken together, the contribution of BCLAF1 to tumourigenesis involves different cancer signalling 
pathways, such as cell death signalling, cell growth and division and DDR signalling pathways 
and cancer associated BCLAF1 variants deregulate BCLAF1 downstream gene expression 
involved in the above mentioned cancer signalling pathways leading to uncontrolled cell growth, 
survival and accumulation of apoptosis-resistant cells, defective DNA repair and genomic 




















The investigation of cancer molecular events is of immense importance, as it provides a distinct 
direction by which to fight cancer. This study set out to identify the role and contribution of 
BCLAF1 in tumourigenesis. Transformed human lung fibroblasts, the CT1 cell line, was used a 
model to examine and understand the molecular role of BCLAF1 knockdown in tumourigenesis. 
BCLAF1 has previously been reported to be mutated  in various tumours and differently expressed 
in various tumour types (Kasof et al., 1999; Zhou et al., 2014). In this study, we investigated the 
expression of BCLAF1 in different human cancer cell lines. BCLAF1 expression was found to be 
supressed in all human cancer cell lines examined. Extremely low levels of expression of BCLAF1 
was detected in the MDA-231 cell line, both at protein and RNA levels. Although BCLAF1 
deregulation alone may not be sufficient to initiate tumourigenesis, BCLAF1 deregulation alters 
the expression of a number of downstream genes involved in apoptosis, damage DNA repair and 
cell cycle regulation. Hence, differential expression of genes downstream of BCLAF1 was 
observed. 
 The functional consequences of BCLAF1 on apoptosis, cell cycle, and damaged DNA repair and 
its contribution to carcinogenesis was demonstrated by the knockdown of BCLAF1 gene 
expression in the CT1 cell line using RNA interference technology, as RNAi ensures the specific 
silencing of gene expression with no off-target effects. This study showed that BCLAF1 
knockdown attenuated the expression of apoptotic genes such as BAX and Caspase-3 both at RNA 
and protein levels. However, antiapoptotic BCL2 and BCL-XL expression in CT1 cells were largely 
unaffected when BCLAF1 expression was inhibited. This study also determined that H2AX is a 
downstream gene of BCLAF1 and that siRNA-mediated BCLAF1 knockdown downregulates 
damaged DNA repair genes EXO1, ATRIP, BACH1 as well as H2AX expression. In addition, our 
study suggested that the downregulation of H2AX in BCLAF1 depleted cells contributes to their 
inability to resolve γH2AX-marked DNA sites, resulting in elevated defective DNA repair in 
BCLAF1 depleted CT1 cells in comparison to control cells. The inhibition of BCLAF1 resulted in 
the downregulation of P53 and a slight accumulation of P21, resulting in a P21-depedent G1 cell 





Figure 4.1 The downstream effects of BCLAF1 knockdown. In the cytoplasm of siRNA-mediated BCLAF1 
knockdown cells, the expression of apoptotic genes such as BAX and Caspase-3 is inhibited, which results in anti-
apoptosis signals in cells. In the nucleus, the suppression of BCLAF1 leads to weakened Ku70/DNA-PKcs complex 
but kept the expression of BCL-2 and BCL-XL instead, subsequently reducing the activity of DSB repair. The depletion 
of BCL-2 enhances the DNA binding activity of the Ku70/DNA-PKcs complex for accelerating DNA repair. The 
knockdown of BCLAF1 downregulates the expression of H2AX, hence, reduced levels of γH2AX production 
contributing to cells inability to resolve γH2AX-marked DNA break sites. This results in elevated defective DNA 
repair and genomic instability. Consistent with the role of BCLAF1 in mRNA splicing of DNA repair genes EXO1, 
ATRIP, BACH1, depletion of BCLAF1 attenuated/inhibits the expression of EXO1, ATRIP, BACH1. BCLAF1 
knockdown results in the downregulation of P53, subsequently resulting in P53-dependent uncontrolled growth of 
cells. Furthermore, BCLAF1 deficiency upregulates P21, through an unknown P21-promoter, resulting in a P21-
depedent G1 cell cycle arrest. Modified from (Lee, Yu, et al., 2012). 
Taken together, these results show that abrogation of BCLAF1 expression in CT1 cells can result 
in dysregulation of several cancer signalling pathways. Moreover, BCLAF1 deficiency resulted in 
P53-dependent uncontrolled growth of cells, survival and accumulation of apoptosis-resistant 






Materials and methods 
5.1 Cell lines and cell culture 
5.1.1 Cell lines 
Transformed immortalized keratinocyte cell line, HaCaT; lung transformed fibroblasts, CT1; 
cervical cancer cell line, HeLa; breast cancer cell line, MDA-231 and two oesophageal cancer cell 
lines; KYSE30 and WHCO1 were used in the study and CT1 was used as model cell line for 
transfections in this study. HeLa (ATCC® CCL­2™), MDA-231 (ATCC® HTB-26™) and 
HaCaT (the ATCC number is no longer available) cell lines are from the American Type Culture 
Collection (ATCC); CT-1 was a gift from (Namba et al., 1980), WHCO1 and KYSE30 was a gift 
from (Veale, 1984). 
5.1.2 Cell culture and maintenance 
Cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% fetal bovine serum (FBS) and 1% (P/S) penicillin/streptomycin (complete medium) in a 
humidified environment and 5% CO2 at 37˚C. The medium was replaced every 2 to 3 days by 
aspirating the used medium and washing the cells with 10ml of Phosphate Buffered Saline (PBS) 
and fed with fresh complete medium. Cells were sub-cultured every 4 to 5 days, by removing the 
medium, rinsing with PBS incubating in 0.05% trypsin-10 mM EDTA in PBS for 3 minutes.   Once 
the cells had detached, the trypsin- was inactivated by adding 5 ml of complete medium. Cells 
were pelleted by centrifugation at 4000 rpm for 5 minutes, re-suspended in 3 ml of complete 
medium and 1 ml aliquots were re-plated in fresh plates. For the preparation of frozen stocks, the 
cells were re-suspended in cell freezing medium (70 % DMEM, 20 % FBS and 10 % DMSO) by 
gently pipetting. The cells were stored in liquid nitrogen. 
5.2 Genetic interference and modification  
5.2.1 RNA interference 
For the inhibition of gene expression, siRNA was used, BCLAF1 siRNA (EHU069911-20UG) was 
obtained from Sigma Aldrich. siRNA consisting of a scrambled sequence (SIC001, Sigma Aldrich) 
was used as a non-silencing control. Cells in DMEM containing 10% FBS without antibiotics were 
transiently transfected with 20nM siRNA using MISSION® siRNA Transfection Reagent (S1452-
100µL, Sigma Aldrich). RNA and Protein were harvested 24 hours post-transfection (as described 
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in Sections 5.3.1 and 5.4.1 respectively) and the downstream effects of cellular gene expression 
were examined by qRT-PCR and Western Blot analysis respectively (as described in Sections 5.3.2 
and 5.4.2). The effect of the respective siRNAs on cell cycle and DNA repair was determined 
using the flow cytometry and immunofluorescence assays respectively. Briefly, cells were seeded 
either on cover slips or directly into 6-well tissue culture plates for immunofluorescence and flow 
cytometry respectively, transfected with 20 nM siRNA and incubated for 24 hours. The effect of 
BCLAF1 siRNA on cell cycle and DNA repair was assayed using the flow cytometry and 
immunofluorescence reagents respectively. 
5.2.2 CRISPR/Cas9 BCLAF1 gene editing transfection  
CT1 cells were cultured in DMEM containing 10% FBS without antibiotics in 24-well plates at a 
density of 100,000 cells per well, 24 hrs before transfection. The cells were transiently transfected 
with the recommended combination of mKate2-Cas9 expression plasmid DNA (100 µg/µL), 
(Dharmacon Inc., #U-004100-120), CRISPR-Cas9 synthetic tracrRNA (10 µM) , (Dharmacon 
Inc., #U-002000-20), and two human BCLAF1 crRNAs (5 nM each), (Dharmacon Inc.), targeting 
exon 4; target sequence: GAGGAATGAGACGACCTTAT, genomic location and PAM: hg38|-
chr6:136278665 GGG and exon 7; target sequence: CGAAGTGAACCGCTCGTTTA, genomic 
location and PAM: hg38|+chr6:136273138-136273160 GGG using DharmaFECT Duo 
transfection reagent (Dharmacon Inc., #T-2010-03) as per the manufacturer’s protocols. Cells were 
incubated for 72 hours before proceeding with cell sorting and gene editing studies. 
5.2.3 Fluorescence-activated cell sorting (FACS) 
72 hours post transfection, the old medium was aspirated and trypsinized the cells in 0.5 ml of 
0.05% trypsin-EDTA as described above in Section 5.1.2. The cell pellet was collected by 
centrifugation at 4000 rpm for 3 minutes, re-suspended in 2 ml of DMEM in 5 ml falcon round-







Table 5.1 PCR primer sequences 
Primer Sequence Product size 
 FW 5'- AGA TCG GAA GTG ACG GAG -3'  
Primer set 1 RV 5'- CAT TCT GTG GTG CGA TTG TC -3' 1176 bp 
 FW 5'- TTC ATC ACA TCC CTT CAC G -3'  
Primer set 2 RV 5'- TTC CTT GCG TCT GTC CTT C -3' 1877 bp 
Primer set 1-Forward primer + FW 5'- AGA TCG GAA GTG ACG GAG -3'  
Primer set 2-Reverse primer RV 5'- TTC CTT GCG TCT GTC CTT C -3' 2999 bp 
 
5.3 RNA Extraction and quantification and PCR analysis 
5.3.1 RNA Extraction and quantification 
RNA was extracted from cells using QIAzol Lysis Reagent (QIAGEN, Hilden, Germany). The 
medium was aspirated, and cells were washed with cold PBS. Appropriate volume of QIAzol 
respective to the size of the plate was added onto the cells (1 ml for 10 cm plates and 0.5 ml for 6-
well plates). The cells were lysed by scrapping them off the plate using the cell scrapper and 
transferred to 1.5 ml Eppendorf tubes. The homogenized sample was incubated for 5 minutes at 
room temperature. 200 µl of chloroform was added shaken vigorously for 15 seconds to mix well 
and incubated for 3 minutes at room temperature. The samples were then centrifuged at 14000 rpm 
for 15 minutes at 4°C. The upper aqueous layer was transferred to a fresh labelled tube and 0.5 ml 
of isopropanol was added, mixed thoroughly by shaking (do not vortex) for 15 seconds and 
incubated at room temperature for 10 minutes. The samples were then centrifuged at 14000rpm 
for 20 minutes at 4°C to pellet the RNA. The supernatant was carefully removed and added 1ml 
75% DEPC-ethanol and vortexed on low for 5-10 seconds to wash the pellet thoroughly, 
centrifuged at 12000 rpm for 5 minutes at 4°C to re-pellet the RNA. The supernatant was carefully 
removed, and air dried at room temperature for 10 minutes. The pellet was then dissolved in 20-
30 µl DEPC treated-water by gentle pipetting and incubated at 55°C for 5 minutes. RNA was 
quantitated on a NanoDrop 2000/2000c Spectrophotometer (Thermo Scientific, IL, USA) and 




5.3.2 cDNA synthesis and qRT-PCR analysis 
For first strand cDNA synthesis, total RNA was reverse-transcribed using ImProm-II Reverse 
Transcriptase (Promega, Madison, WI, USA) according to the manufacturer's instructions as 
indicated in (Table 5.2). 5 μg template mRNA, 1 µl oligo dT and dH2O were mixed to a final 
volume of 9 µl. This mixture was heated for 10 minutes at 70 ˚C to denature any secondary 
structure in the RNA followed by annealing to the oligo dT primers. The mixture was chilled on 
ice for 5 minutes. The second master mix (Table 5.3) of MgCl2, 5x first strand synthesis buffer, 
dNTPs mix, RNAse inhibitor and reverse transcriptase were added and incubated for 2 hours at 
42°C, followed by 10 minutes at 70°C to inactivate the reverse transcriptase. 
Table 5.2 cDNA synthesis master mix 1 
5μg mRNA Oligo dT ddH20 Total 
Y 1 X 9 μl 
 
Table 5.3 cDNA synthesis master mix 2. 
Reagents Volume (μl) 
5X first strand synthesis buffer 5 
dNTPs mix 1 
RNase inhibitor 1 
MgCL2 2 
Impromp II Reverse Transcriptase 1 
ddH2O 1 
Total  9 
 
One microliter of the cDNA was subsequently amplified using the KAPA SYBR qPCR Master 
Mix (KAPA SYBR Fast qPCR Kit, KAPA Biosystems) on a Roche Lightcycler 480 II. Briefly, to 
a mixture of SYBR Green PCR Master Mix, 20 μM of forward and reverse primers, as well as 1μl 







Table 5.4.  qRT-PCR mixture set up for each gene 
Reagents Volumes (μl) 
SYBR Green PCR Master Mix 5 
Forward primer (20 uM) 1 





Table 5.5 Sequences of primers used for real‐time RT‐PCR analysis 
Primer Sequence Annealing Temperature (°C) 
BCLAF1 FW 5'- GGG GCG TAT TGA TGT TGA AAG -3' 
RV 5'- GAG CAC GAG GAC AGA CTA AAC -3' 
 
BAX FW 5’- GGT TGT CGC CCT TTT CTA CT -3’ 
RV 5’- AAG TCC AAT GTC CAG CCC AT -3’ 
 
Caspase-3 FW 5'- ACA TGA CTC AGC CTG TTC C -3' 
RV 5'- GCC TCA CCA CCT TTA GAA C -3' 
 
Caspase-9 FW 5’- GTG AAC TTC TGC CGT GAG TC -3’ 
RV 5’- GCA AAG CCA GCA CCA TTT TC-3’ 
 
BCL2 FW 5'- CTG CAC CTG ACG CCC TTC ACC -3' 
RV 5'- CAC ATG ACC CCA CCG AAC TCA AAG -3' 
 
BCL-XL FW 5'- GAT CCC CAT GGC AGC AGT AAA GCA AG-3' 
RV 5'- CCC CAT CCC GGA AGA GTT CAT TCA CT -3' 
                 
 
P53 FW      5’- CTG CTC AGA TAG CGA TGG TCT G -3’ 
RV      5’- TTG TAG TGG ATG GTG GTA CAG TCA -3’ 
 
P21 FW     5’- ACC TCA CCT GCT CTG CTG C -3’ 
RV      5’- ATT AGG GCT TCC TCT TGG AGA -3’ 
                   60 
EXO1 FW 5'- CTC AAG TGG GAG AGG CTT TG -3' 
RV 5'- AAC GCT GTC CTG GAA GAG AA -3' 
 
ATRIP FW 5'- AGG CTG CTA ACC TCT GTC GGA -3' 
RV 5'- CAG AGA CTC CCA GCA AGG TC -3' 
 
BACH1 FW 5'- CTG CCA CCT CCC AAC ATA GT-3' 
RV 5'- GAG ATG CAG CAC AGA CCA AA -3' 
 
Ku70 FW 5’- GGC TGT GGT GTT CTA TGG -3’ 
RV 5’- CCC TTA AAC TGG TCA AGC -3’ 
 
H2AX FW 5'-TCC CTT CCA GCA AAC TCA AC-3' 
RV 5'- CCA TCT AAA ACT CCC CAA TGC-3' 
 
BRCA1 FW 5'-CAT GCT GAA ACT TCT CAA CCA-3' 
RV 5'-TGT AGG CTC CTT TTG GTT ATA T-3' 
 
GAPDH  FW      5’- GGCTCTCCAGAACATCATCC - 3’  






5.3.3 Preparation of a 1% agarose gel and electrophoresis  
1% Agarose gels were prepared by boiling 5g agarose powder in 500 ml 1X TBE electrophoresis 
buffer. After the solution had cooled down to ̴ 42°C, 30 μl of ethidium bromide (0.5 µg/ml) was 
added to the solution and mixed properly. The gel was poured into the gel tank, combs were 
inserted and allowed to set and solidify at room temperature. 1X TBE electrophoresis buffer was 
added to the tank and used as the running buffer. The total of 10 μl cDNA was mixed with 3 μl of 
DNA loading buffer and the mixture was run on 1% agarose gel. Electrophoresis was done at 100 
V for 90minutes. The gels were then digitally photographed using UVP BioSpectrum Imaging 
System (UVP, USA). 
5.4 Protein extraction and Western blot analysis 
5.4.1 Protein extraction 
Cells were grown to 80% confluency, washed with cold PBS and lysed in RIPA buffer and the 
culture plates were incubated on ice on a shaker for 30 minutes. A cell scraper was used to dislodge 
the cells. The lysate was transferred to a 1.5 ml tube and sonicated once for 10 seconds (Heat 
System-Ultrasonics, USA). The lysate was centrifuged at 4°C for 15 minutes at 14000 rpm and 
the supernatant was collected, leaving the pellet consisting of insoluble cell debris. Protein 
concentrations were quantified using the BCA protein assay kit (Thermo Scientific, USA), 
according to manufacturer’s instruction. Briefly, a standard curve with concentrations between 0 
and 2000 μg/ml was constructed using Bovine Serum Albumin (BSA). 200 µl of working reagent 
was added to the standards and samples in a 96-well plate. The plate was incubated for 30 minutes 
at 37°C, and the absorbance was measured at 595 nm using the Multiskan FC plate reader (Thermo 
Scientific, USA). To determine the protein concentrations, the equation of the slope of the standard 
curve was used.  
5.4.2 Western blot analysis 
Proteins were separated on sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS 
PAGE). The SDS PAGE gels were made with 4% stacking gel and 10% separating gel (Table 5.7 
and Table 5.6) respectively. Equal protein concentrations (30 μg) were heat denatured at 95°C for 
5 minutes in 1x loading dye, cooled and loaded into their respective wells. A PAGE Ruler Plus 
Prestained Protein Ladder (Thermo Scientific, USA) was loaded to determine the size of the 
protein bands (10-250 kDa) of interest and electrophoresed at 100 V for 2 hours. Proteins were 
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transferred to ECLTM nitrocellulose membrane in 1X transfer buffer for 90 minutes at 4°C. The 
membranes were rinsed thrice for 10 minutes in 10 ml TBST on a shaker at room temperature. To 
reduce nonspecific binding, membranes were blocked in 10 ml 5% non-fat milk in TBST for 1 
hour on a shaker at room temperature, following the incubation of membranes at 4°C overnight on 
a shaker with primary antibodies. Western blot analyses were performed using the rabbit 
polyclonal anti-BTF (ab107177), rabbit polyclonal anti-caspase-3 (phospho S150) (ab59425), 
rabbit polyclonal anti-Caspase-9 (ab209495), rabbit monoclonal anti-BAX (ab182733), rabbit 
polyclonal anti-Bcl-2 (ab115807), rabbit polyclonal anti-Exonuclease 1 (ab106303), rabbit 
polyclonal anti-gamma H2AX (phospho S139) (ab11174), rabbit polyclonal anti-p53 (ab17990), 
rabbit polyclonal anti-p21 (ab219811), and rabbit polyclonal anti-BTF (ab107177) primary 
antibodies (Abcam Biotechnology company). The following day, membranes were washed thrice 
for 10 minutes in 10 ml TBST at room temperature, then incubated with horseradish peroxidase 
(HRP)-conjugated secondary antibodies at room temperature for 1 hour on a shaker. The protein 
of interest was detected using the Lumiglo ReserveTM Chemiluminescent Substrate Kit (KPL, 
USA). The UVP BioSpectrum Imaging System (UVP, USA) was used to visualise the protein 
bands of interest. 
The primary and secondary antibodies were stripped off the membranes by washing once with 10 
ml 1M Glycine pH 2.5, then a wash with 10 ml Tris pH 7.5 and thrice using 10 ml TBST. The 
membranes were then incubated with 10 ml 5% non-fat milk in TBST for 1 hour before re-probing 
with different primary antibodies. 
 




Table 5.6 Proteins molecular weight  












5.5 Cell cycle analysis 
For cell cycle analyses, CT1 cells were plated in 6-well plates, transfected with 20 nM siRNA and 
incubated for 24 hours (as described in Section 5.2.1). Cells were harvested and 800 µl of ice cold 
absolute ethanol was added to fix the cells before storage at -20°C for a day. The samples were 
thawed at room temperature, centrifuged at 4000 rpm for 5 minutes and the ethanol was decanted 
carefully. The pellet was resuspended in 1 ml PBS and the tube was centrifuged at 4000 rpm for 5 
minutes. The PBS was discarded and 100 µl of RNAse solution (1:20 dilution of a 10 μg/ml 
solution in PBS) was pipetted into each tube followed by incubation at 37°C for 15 minutes. 500 
µl of propidium iodide (1:100 dilution in PBS) was added to each sample for 30 minutes before 
proceeding to visualise and analyse the samples using the FACScan Cell Sorter (Benton 
Dickinson, NJ, USA) and the Cellquest and Modfit (Benton Dickinson, NJ, USA) analysis 
software. 
5.6 Apoptosis assays 
To assess the effects of BCLAF1 siRNA effects on apoptosis, apoptosis detection assay was 
performed using FITC Annexin V Apoptosis Detection Kit, (BD Pharmingen™) according to the 
manufacturer's instruction. The following controls were used to set up compensation and 
quadrants: unstained cells, cells stained with Annexin V-FITC (no PI), cells stained with PI (no 
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Annexin V-FITC). The cells were properly gated dual parameter dot plots of X-axis, FITC 
fluorescence versus Y-axis, PI fluorescence has been shown in logarithmic fluorescence intensity. 
Differentiation of cell population was done on flow cytometer using the FACScan Cell Sorter 
(Benton Dickinson, NJ, USA). The apoptotic activity of each sample was measured 24 hr after 
BCLAF1 siRNA transfection.  
5.7 UV exposure and DNA damage validation 
The medium was carefully removed from each well by tilting the 6-well plate and aspirating from 
the edge. Cells were exposed to different doses (0J/M2, 40J/M2, 200J/M2, 500J/M2) of UV light. 
DNA was extracted from each sample by adding 1ml of SDS -Tris-EDTA (SDS-TE) (1 ml of 10% 
SDS in 10 mM TE buffer pH 8) buffer to cells, following the addition of 10 μl of proteinase K 
(100 μg/ml). The mixture was incubated at 50°C overnight. The following day, RNA was removed, 
and the DNA denatured   by the addition of 66 μl of 5M NaOH and incubation at 37°C for 1 hour. 
40 μl of the DNA extracts were ran on a 1% agarose gel at 100 V for 90 minutes for DNA damage 
validation. 
5.8 Immunofluorescence analysis for BCLAF1 siRNA effects on DNA repair 
24 hours post BCLAF1 siRNA transfection, the medium was carefully removed from cells plated 
on cover slips and the medium placed in 12ml falcon tubes separately. Cells were exposed to 
40J/M2 and placed back the old media containing the transfection complexes onto the cells. At the 
indicated time points, cells were permeabilized in absolute methanol for 5 minutes at -20°C and 
immediately fixed at room temperature for 5 minutes with 4% paraformaldehyde. After three 
rinses with PBS, blocking solution (1% BSA, 0.5% TritonX-100 in PBS) was added for 1 hour. 
100 µl of BCLAF1 (BCLAF1 knockdown validation) or γH2AX (DNA pair activity) primary 
antibodies (1:500 dilution) were added and the coverslips were incubated overnight at 4°C in a 
humidified chamber. After three washes with PBS for 10 minutes, goat anti rabbit IgG-CFL 488 
(sc-362262) secondary antibodies (1:1000 dilution) were added and incubated for 90 minutes at 
room temperature in a dark humidified chamber. Antibodies used were rabbit polyclonal anti-BTF 
(ab107177), rabbit polyclonal anti-gamma H2AX (phospho S139) (ab11174). The coverslips were 
washed three times with PBS, counter stained with 100µl 0.5ug/ml DAPI (DNA stain) for 10 
minutes then rewashed once with 10ml PBS at room temperature. Flouromount aqueous Mounting 
Medium (Sigma-Aldrich Cat. No. F4680) was used to mount the coverslip upside down on the 
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glass slide and the slides were stored at room temperature in the dark overnight and placed at 4°C 
until viewing under the Olympus 1X81 Inverted Fluorescent microscope using the cellSens 
Dimension Software (Olympus Imaging Software).  
5.9 Statistical analysis 
All experiments were performed in triplicate. For all data comparisons, the Student’s t test was 
performed using GraphPad prism. A P value of <0.05 was considered statistically significant and 
*p < 0.05, **p < 0.01, ***p < 0.001. 
5.10 Solutions and buffers 
5.10.1 Protein solutions  
RIPA buffer   
25 ml 1 M Tris pH 7.4  
5 ml NP-40  
2.5 g Na-deoxycholate  
0.5 g SDS  
15 ml NaCl  
2 ml 0.5M EDTA  
1.05 g NaF  
Dissolve in 300 ml dH2O and dilute to 500 ml with dH2O 
 
 10% Separating Gel 
Table 5.7 10% Separating gel recipe 
           X1 
ddH2O 2.72 ml 
1M Tris Buffer pH 8.8 3.75 ml 
30% Acrylamide 3.3 ml 
10% SDS 100 μl 
10% APS 100 μl 






4% Stacking Gel 
Table 5.8 4% Stacking gel recipe 
           X1 
ddH2O 3.65 ml 
1M Tris Buffer pH 6.8 0.625 ml 
30% Acrylamide 0.650 ml 
10% SDS 50 μl 
10% APS 25 μl 
Tetramethylethylenediamine (TEMED) 5 μl 
 
1 M Glycine pH 2.5 
Add 75 g Glycine in 800 ml of ddH2O, pH 2.5 using HCl. 
Adjust the volume to 1 L with ddH2O 
Autoclave. 
10X Running Buffer 
30 g Tris base  
144 g Glycine  
10.0 g SDS  
Dilute to 1 litre with dH2O 
1X Running Buffer 
100 ml 10X Running buffer 
Bring to 1 L with ddH2O 
 
 
10X Transfer Buffer 
30 g Tris base  
144.1 g Glycine  
Dilute to 1 litre with dH2O 
1X Transfer Buffer 
100 ml 10x Transfer buffer 
200 ml methanol 
Bring to 1 L with ddH2O 
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4 M NaCl 
Dissolve 292.2 g NaCl in a final volume of 1 L ddH2O 
TBST 
250 μl Tween 20  
30 ml 5 M NaCl  
50 ml 1 M Tris pH 7.5  
Dilute to 1 litre with dH2O 
4% non-fat milk blocking solution  
2.5 g non-fat milk powder  
Dissolve in 50 ml with TBST 
4X protein loading dye   
2.5 ml 1M Tris pH 6.8 
4 ml 20% SDS  
0.2 ml 0.1% Bromophenol Blue  
4 ml Glycerol   
50 μl β-mercaptoethanol 
Blocking solution for immunofluorescence microscopy  
0.5 g BSA  
50 μl Triton X-100  
Dilute to 50 ml with PBS 
10% Ammonium Persulfate (APS) 
Ammonium persulfate 5 g 
ddH2O 50 ml 
Store at -20°C 
1 M Tris pH 7.5 
Add 121 g Tris base to 800 ml ddH2O 
Adjust pH with concentrated HCl to pH 7.5 
Add distilled water up to one litre 
Autoclave. 
1 M Tris pH 6.8 
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Add 121 g Tris base to 800 ml ddH2O 
Adjust pH with concentrated HCl to pH 6.8 
Add distilled water up to one litre 
Autoclave. 
1 M Tris pH 8.8 
Add 121 g Tris base to 800 ml ddH2O 
Adjust pH with concentrated HCl to pH 8.8 
Add distilled water up to one litre 
Autoclave. 
Glycine pH 2.5 
10% sodium dodecyl sulphate (SDS)  
Dissolve 10 g sodium dodecyl sulphate in 80 ml distilled water (heat to 80°C),  
Bring to 100 ml with distilled water 
5.10.2 RNA and DNA solutions 
DEPC water  
1 ml DEPC in 1 litre dH2O.   
Incubate for 1 hour at 30°C and autoclave to remove the DEPC. 
75 % DEPC- Ethanol  
75 ml absolute ethanol   
25 ml DEPC-treated water. 
0.5 μg/ml DAPI stain 
5 ul 0.5 mg/ml DAPI stock solution in 4.5 ml PBS 
0.5 M EDTA, pH 8.0  
Add 18.61 g of Na2EDTA.2H2O to 80 ml ddH2O 
Adjust the pH to 8.0 with 10 NaOH  
Add distilled water to a final volume of 100 ml 
Autoclave and store at room temperature. 
5 M NaOH 
Dissolve 20.0 g of NaOH pellets in 80 ml ddH2O 
When cooled, bring to the final volume 100 ml. 
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10X TBE buffer 
Dissolve 108 g Tris in 800 ml 
Add 55 g Boric Acid (Mix) 
Add 40 ml 0.5 Na2EDTA 
Adjust volume to 1 L, store at room temperature. 
1% Agarose gel 
5 g of Agarose powder 
500 ml of 1X TBE buffer 
5.10.3 Tissue culture solutions 
70 % Ethanol  
70 ml of absolute ethanol  
Add 30 ml of distilled water 
Freezing media 
70 % Fetal bovine serum  
20 % DMEM media 
 10 % Dimethylsulphoxide (DMSO) 
PBS (pH 7.4) 
154 mM NaCl  
2.7 mM KCl 
5.6 mM Na2HPO4 or Na2HPO42H2O 
1 mM KH2PO4  
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